Mark Sullivan

Mark Sullivan has 11 years executive management, advisory board, and board of directors experience in biotechnology and 28 years of experience in clinical development within the biotechnology, large pharmaceutical, contract services, and academic sectors. His drug development experience encompasses project leadership of five biopharmaceutical products, with his most recent program securing FDA approval in June 2018, and extensive practical experience implementing clinical studies across all stages of development.

Mr. Sullivan led the team responsible for one of GHIF’s more rewarding social and financial investments: seeing the moxidectin program through the final stages of development and securing regulatory approval for the drug as the first new treatment for onchocerciasis registered with the FDA in more than 20 years.

Publications

Journal articles

• De Rose R; Sullivan MT; Dale CJ; Kelleher AD; Emery S; Cooper DA; Ramshaw I; Boyle D; Kent SJ, 2006, 'Dose-response relationship of DNA and recombinant fowlpox virus prime-boost HIV vaccines.', Human Vaccines, vol. 2, pp. 134 - 136

• De Rose R; Chea S; Dale C; Reece J; Fernandez C; Wilson K; Thomson S; Ramshaw I; Coupar B; Boyle D; Sullivan MT; Kent S, 2005, 'Subtype AE HIV-1 DNA and recombinant Fowlpoxvirus vaccines encoding five shared HIV-1 genes: safety and T cell immunogenicity in macaques', Vaccine, vol. 23, pp. 1949 - 1956, http://www.sciencedirect.com/science/article/B6TD4-4DS4075-2/2/4ac957fc8ef72984bea88998a0965b95

Education

• BSc Deakin University (1984 — 1988)

Skills

The most important

• GCP
• Regulatory Affairs
• Commercialization

Other

Pharmacology, Molecular Biology, Technology Transfer, Oncology, Drug Discovery, Immunology, Biopharmaceuticals, Drug Development, Lifesciences, Clinical Trials, Life Sciences, Pharmaceutical Industry, Infectious Diseases, Clinical Research, Clinical Development, Vaccines, Biotechnology